Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B

NCT02048111 is registered in ClinicalTrials.gov with Cangene Corporation as lead sponsor.

NCT NCT02048111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02048111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B
Lead sponsor
Cangene Corporation
Phase
Phase 3
Overall status
Withdrawn
Start date
March 31, 2014
Completion date
November 30, 2015
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b